GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » ROE % Adjusted to Book Value

Pangaea Oncology (XMAD:PANG) ROE % Adjusted to Book Value : -6.83% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology ROE % Adjusted to Book Value?

Pangaea Oncology's ROE % for the quarter that ended in Jun. 2024 was -18.77%. Pangaea Oncology's PB Ratio for the quarter that ended in Jun. 2024 was 2.75. Pangaea Oncology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -6.83%.


Pangaea Oncology ROE % Adjusted to Book Value Historical Data

The historical data trend for Pangaea Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology ROE % Adjusted to Book Value Chart

Pangaea Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.69 -5.84 -2.28 -7.52 -9.18

Pangaea Oncology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.90 -7.59 -3.93 -16.00 -6.83

Competitive Comparison of Pangaea Oncology's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Pangaea Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangaea Oncology's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pangaea Oncology's ROE % Adjusted to Book Value falls into.



Pangaea Oncology ROE % Adjusted to Book Value Calculation

Pangaea Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-22.87% / 2.49
=-9.18%

Pangaea Oncology's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-18.77% / 2.75
=-6.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pangaea Oncology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangaea Oncology Business Description

Traded in Other Exchanges
N/A
Address
Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines